persist
hbv
cccdna
variou
host
immun
defect
shown
two
main
obstacl
hbv
clearanc
block
singl
target
suffici
achiev
function
cure
chb
small
percentag
chb
patient
could
attain
function
cure
antivir
treatment
follow
interferon
therapi
therapeut
vaccin
chb
show
substanti
efficaci
human
hbsab
could
effici
block
hbv
infect
decreas
hbsag
level
mice
model
research
show
serum
viral
dna
hbsag
load
becam
low
undetect
antivir
hbsab
treatment
therapeut
vaccin
myic
add
induc
effect
host
humor
intrahepat
cellular
antihbv
immun
respons
rapid
effici
clearanc
hbv
hbsag
base
optim
antivir
treatment
potent
human
hbsab
rapidli
decreas
serum
hbsag
follow
boost
host
activ
immun
provid
novel
strategi
function
cure
chb
million
individu
live
chronic
hbv
infect
high
risk
death
lifethreaten
complic
liver
cirrhosi
hepatocellular
carcinoma
currentlyapprov
drug
chb
includ
nucleo
ide
analogu
na
pegyl
interferon
pegifn
rare
achiev
function
cure
domin
challeng
achiev
chb
cure
present
stabl
presenc
coval
close
circular
dna
within
host
hepatocyt
immun
toler
primarili
induc
high
hepat
b
surfac
antigen
hbsag
load
thu
function
cure
chb
character
loss
hbsag
presenc
hbsab
urgent
need
gener
accept
block
singl
target
suffici
reach
function
cure
recent
clinic
data
indic
promis
potenti
combin
therapi
chb
treatment
instanc
pegifn
tenofovir
disoproxil
fumar
tdf
combin
increas
hbeag
seroconvers
loss
hbsag
hbeag
hbv
dna
low
chb
patient
patient
display
lowlevel
serum
hbsag
longterm
antivir
drug
treatment
hbsag
loss
observ
receiv
addon
pegifn
treatment
time
sever
monoclon
antibodi
target
hbsag
develop
evalu
differ
preclin
clinic
stage
antibodi
capabl
reduc
serum
hbsag
therefor
may
play
pivot
role
combin
therapi
chb
function
cure
recent
hypothes
base
transient
clearanc
serum
viral
dna
hbsag
window
stage
activ
immun
hbv
might
initi
effect
host
immun
respons
versu
hbv
achiev
function
cure
chb
articl
hbv
dna
hydrodynam
inject
hdihbv
mice
adenoassoci
viru
infect
base
aavhbv
mice
use
experiment
model
antivir
drug
tdf
given
oral
inhibit
viru
replic
follow
inject
antihb
neutral
monoclon
antibodi
show
synergist
effect
decreas
viral
dna
serum
hbsag
load
window
stage
hbsagantihb
complex
myic
administ
stimul
activ
immun
respons
therapeut
efficaci
shown
gener
glp
product
monoclon
antibodi
describ
previous
human
hbig
bayhep
b
manufactur
bayer
co
ltd
unrel
control
antibodi
antimerscov
human
monoclon
antibodi
antibodi
concentr
determin
absorb
nm
use
nanodrop
spectrophotomet
thermo
fisher
hbsag
mous
hbsab
immun
complex
myic
produc
report
previous
five
sixweekold
male
mice
purchas
sinobritish
sipprbk
lab
anim
ltd
co
shanghai
china
mice
kept
specif
pathogenfre
condit
anim
depart
shanghai
public
health
clinic
center
sphcc
hdihbv
mous
model
construct
previous
describ
hydrodynamicinject
plasmid
contain
hbv
sequenc
clone
chb
patient
hbsagposit
mice
use
ten
week
inject
aavhbv
mous
model
construct
inject
fiveplu
molecular
medicin
institut
china
via
tail
vein
use
evalu
combin
therapi
four
week
establish
inject
via
tail
vein
dose
mgkg
mg
per
mice
hbig
use
iu
iuml
per
inject
tdf
intragastr
administr
mgkg
everi
day
interv
mice
bled
via
retroorbit
sinu
hbsag
hbeag
aminotransferas
alt
level
quantifi
use
roch
coba
shanghai
labway
clinic
laboratori
co
ltd
hbv
dna
level
sera
determin
hbv
dna
quantit
fluoresc
diagnost
kit
shengxiang
co
ltd
china
specif
detect
hbsab
gener
immun
mice
sampl
assay
hbsab
detect
kit
kbh
china
titer
hbsab
calcul
standard
curv
serial
dilut
ngml
ngml
mous
monoclon
hbsab
clone
luoyang
bai
aotong
experiment
materi
center
china
mice
euthan
liver
perfus
pb
largest
lobe
divid
two
piec
neutralbuff
formalin
fixat
optim
cut
temperatur
oct
tissuetek
embed
separ
formalinfix
paraffinembed
ffpe
section
use
hbsag
hbcag
detect
rabbit
polyclon
antihbsag
antibodi
fitzgerald
rabbit
polyclon
antihbcag
antibodi
dako
hrplabel
goatantirabbit
secondari
antibodi
zhongshan
jinqiao
biotechnolog
co
ltd
china
stain
slide
scan
pannotam
midi
histech
hbcag
hbsag
express
calcul
imag
j
fiji
accord
dabposit
area
one
caseview
histech
frozen
section
overnightstain
fluorescencelabel
antibodi
mhc
iip
ebiosci
biolegend
granzym
bfitc
invitrogen
biolegend
mhc
ii
costain
rat
lifespan
bioscienc
alexa
fluor
label
goatantirat
invitrogen
appli
stain
follow
mhc
iip
stain
section
stain
hoechst
invitrogen
mount
fluoresc
mount
medium
dako
visual
confoc
microscopi
leica
tc
oil
immers
analyz
leica
applic
suit
la
af
elispot
assay
done
bone
marrow
cell
accord
protocol
describ
previous
briefli
cho
cellexpress
hbsag
north
china
pharmaceut
co
ltd
pb
coat
ethanoltr
pvdf
membran
plate
overnight
bone
marrow
cell
seed
cell
per
well
duplic
incub
h
plate
detect
ad
biotinyl
goat
antimous
igg
abcam
streptavidinconjug
alkalin
phosphatas
bd
bioscienc
spot
visual
bcipnbt
substrat
count
atspot
elispot
analysi
system
cryopreserv
splenocyt
liquid
nitrogen
resuscit
cell
individu
group
plate
cell
per
well
well
plate
stimul
without
peptid
vwlsviwm
h
golgistrop
bd
bioscienc
ad
last
h
block
cytokin
secret
fac
stain
perform
follow
antibodi
pe
bd
bioscienc
fitc
bd
bioscienc
bd
bioscienc
data
acquir
attun
nxt
flow
cytometri
invitrogen
analyz
flowjo
softwar
liver
nonparenchym
cell
isol
describ
harvest
cell
stain
two
separ
panel
antibodi
includ
bd
bioscienc
bd
bioscienc
ebiosci
biolegend
biolegend
blue
biolegend
biolegend
error
bar
data
repres
mean
sem
data
analyz
use
unpair
twotail
mannwhitney
u
test
use
graphpad
prism
statist
softwar
graphpad
softwar
inc
valu
p
consid
statist
signific
p
p
first
hdihbv
mous
model
use
evalu
reduct
hbsag
eight
week
hdi
hbsag
posit
mice
group
accord
rel
hbsag
level
treat
singl
dose
either
irrelev
human
monoclon
antibodi
hbig
use
control
fig
singl
dose
reduc
hbsag
neglig
level
contrast
hbig
one
day
inject
fig
extrem
low
level
serum
hbsag
maintain
day
rebound
day
differ
hbsag
level
among
three
group
disappear
day
contrast
reduct
serum
hbeag
occur
monitor
period
fig
alt
fluctuat
observ
mice
supplementari
fig
addit
mice
exhibit
one
lower
serum
hbv
dna
level
receiv
control
hbig
day
postinfus
fig
hbig
show
inhibitori
effect
mous
model
possibl
due
lack
suffici
neutral
antibodi
polyclon
immunoglobulin
taken
togeth
result
confirm
abl
potent
decreas
hbsag
level
vivo
explor
mechan
hbsag
rebound
day
infus
pharmacokinet
individu
mice
treat
group
assay
averag
show
significantli
longer
halflif
isotyp
control
antibodi
supplementari
fig
interestingli
pharmacokinet
vari
markedli
among
treat
mice
concentr
decreas
slowli
mice
faster
mice
fastest
mice
fig
plasma
hbsab
concentr
calcul
use
roch
comba
show
ident
declin
trend
supplementari
fig
addit
day
concentr
decreas
low
level
mous
fig
accordingli
rebound
hbsag
observ
mous
time
fig
day
mice
lowest
level
display
hbsag
rebound
similarli
four
mice
mice
experienc
hbsag
rebound
day
also
low
level
antibodi
serum
result
suggest
persist
hbsag
suppress
correl
high
hbsab
level
vivo
fullyhuman
origin
antibodi
product
mous
antihuman
antibodi
maha
mice
monitor
supplementari
fig
expect
inject
human
monoclon
antibodi
induc
differ
level
maha
differ
mice
note
mice
display
fastest
clearanc
also
much
higher
level
maha
compar
mice
week
antibodi
infus
find
suggest
vivo
clearanc
partial
due
maha
human
antibodi
may
display
longer
halfliv
test
human
sinc
efficaci
larg
depend
concentr
vivo
inject
two
addit
dose
hdihbv
mice
day
initi
antibodi
infus
fig
expect
inject
quickli
reduc
hbsag
undetect
level
howev
rebound
time
hbsag
shorten
ten
day
third
inject
data
shown
probabl
owe
faster
clearanc
maha
interestingli
prolong
followup
mice
receiv
three
inject
show
gradual
clearanc
hbsag
five
six
mice
group
clear
hbsag
four
month
first
inject
fig
eight
month
first
inject
hbsag
clear
mice
half
mice
control
hbig
group
remain
hbsag
posit
fig
three
six
mice
group
produc
hbsab
one
mous
produc
hbsab
hbig
group
mous
produc
hbsab
group
fig
data
suggest
longlast
blockag
hbsag
may
evok
host
antihbsag
humor
respons
combin
therapi
shown
promis
substanti
therapeut
efficaci
chb
patient
aavhbv
carrier
mous
model
longterm
high
express
hbsag
establish
first
efficaci
combin
daili
regimen
tdf
examin
model
mice
either
intragastr
administ
mgkg
tdf
n
dmso
solut
control
group
day
inject
one
dose
fig
tdf
monotherapi
decreas
serum
hbv
dna
level
one
p
fig
tdf
synergist
reduc
hbv
dna
even
lower
level
comparison
tdf
singl
treatment
p
previou
clinic
studi
use
hbsaghbig
immun
complex
yic
therapeut
vaccin
decreas
hbv
dna
hbeag
seroconvers
found
around
chb
patient
base
sandwich
strategi
examin
combin
effect
tdf
mousederiv
yic
myic
aav
hbvcarrier
mice
mice
group
week
infect
given
tdf
intragastr
throughout
experi
day
tdf
treatment
mice
sequenti
treat
myic
myic
alon
dynam
hbsag
hbeag
level
examin
day
inject
fig
rapid
hbsag
loss
day
five
observ
tdf
sandwich
group
tdf
myic
supplementari
fig
notabl
hbsag
level
sandwich
group
remain
lower
comparison
earlier
hbsag
rebound
seen
group
day
p
fig
myic
group
tdf
myic
show
signific
reduct
hbsag
level
howev
due
continu
hbsag
express
aav
anim
model
hbsag
rebound
seen
treat
group
day
sinc
signific
differ
found
among
group
mice
nineteen
day
one
treatment
treat
mice
two
addit
dose
combin
therapi
day
twenti
thirtyfour
sacrif
mice
three
week
third
inject
fig
dynam
hbsag
chang
three
treatment
analyz
though
signific
reduct
serum
hbsag
level
among
group
two
week
second
inject
third
sandwich
infus
result
declin
hbsag
hbsag
level
significantli
decreas
comparison
tdf
p
tdf
p
tdf
myic
p
three
week
treatment
notabl
three
treatment
signific
reduct
hbeag
level
observ
sandwich
group
compar
control
tdf
group
p
fig
importantli
addit
reduc
hbsag
circul
intrahepat
hbsag
hbcag
express
level
also
markedli
reduc
sandwich
group
p
fig
alt
level
examin
two
week
third
inject
obviou
alt
elev
observ
sandwich
treat
group
comparison
group
supplementari
fig
hematoxylinstain
area
calcul
ensur
similar
hepatocyt
number
count
scope
supplementari
fig
significantli
higher
hbsab
level
observ
elisa
sandwich
treat
mice
compar
group
p
fig
though
signific
compar
myictreat
group
p
three
five
mice
show
signific
elev
hbsab
sandwich
treat
mice
induct
hbsab
close
relat
reduct
hbsag
sandwich
treat
mice
supplementari
fig
confirm
product
hbsab
sandwich
treat
mice
hbsabspecif
secret
plasma
cell
examin
bone
marrow
cell
differ
group
mice
elispot
assay
although
small
dot
observ
myictreat
tdf
myic
tdf
tdfonli
mice
higher
number
bigger
dot
observ
sandwich
tdf
myic
treat
mice
fig
c
p
lymphocyt
spleen
liverdrain
lymph
node
also
analyz
presenc
hbsabsecret
plasma
cell
number
antibodysecret
cell
sandwich
group
increas
though
dot
big
bone
marrow
data
shown
addit
hbsag
specif
cell
respons
also
examin
hbsagspecif
cell
mous
spleen
significantli
increas
third
sandwich
regimen
comparison
tdf
tdfonli
mice
fig
p
p
respect
though
signific
differ
found
compar
myictreat
tdfmyic
mice
p
result
show
sandwich
treatment
evok
effect
hbsag
specif
cell
b
cell
respons
compar
treatment
liver
histolog
reveal
immun
cell
infiltr
spot
portal
area
liver
mice
receiv
myic
tdf
contrast
liver
section
sandwich
treat
mice
show
accumul
island
infiltr
immun
cell
liver
lobul
area
slight
increas
immun
cell
liver
sinusoid
fig
accumul
immun
cell
typic
compris
dozen
mhc
ii
myeloid
cell
aggreg
cell
cell
wherea
mhc
ii
bright
cell
found
section
mice
treat
tdfonli
fig
c
also
compar
control
lymphocyt
increas
granzym
b
express
cytosol
also
found
accumul
myeloid
cell
mainli
account
mhc
ii
cell
sandwich
treat
mice
liver
granzym
b
cell
found
tdfonli
mice
liver
fig
liver
nonparenchym
cell
also
isol
analyz
flow
cytometri
significantli
increas
myeloid
cell
found
among
cell
exclud
neutrophil
fig
f
indic
recruit
antigenpres
cell
loci
furthermor
product
recruit
cell
also
significantli
upregul
sandwich
treat
mice
fig
f
addit
cell
show
decreas
express
sandwich
treat
mice
suggest
high
prolifer
cell
vivo
fig
h
notwithstand
immun
respons
liver
obviou
elev
alt
observ
group
mice
data
shown
pathogenesi
chb
consequ
persist
hbv
replic
express
variou
viral
antigen
complex
defect
acquir
innat
host
immun
respons
hbsag
present
high
particlesml
hbv
carrier
patient
shown
inhibit
host
immun
respons
multipl
mechan
includ
mediat
cell
clonal
deplet
exhaust
hbvspecif
thu
clearanc
hbsag
consid
crucial
step
restor
host
immun
achiev
function
cure
chb
therefor
rapid
effici
decreas
load
hbsag
induct
effect
host
immun
two
arm
seek
function
cure
howev
among
strategi
studi
use
activ
immun
base
transient
clearanc
hbv
hbsag
window
stage
combin
therapi
previous
pursu
chb
patient
anim
patient
combin
ifn
na
assess
sever
clinic
trial
howev
strategi
shown
increas
hbsag
loss
seroconvers
rate
small
proport
chb
patient
whose
serum
hbsag
level
miuml
welldesign
experiment
studi
mice
found
multipl
mous
hbsab
infus
follow
combin
hbsag
vaccin
agonist
induc
hbsab
hbvspecif
ctl
respons
aavhbv
mice
model
howev
mous
antibodi
infus
interv
week
need
modifi
make
feasibl
treatment
patient
studi
aim
gener
strategi
applic
futur
clinic
set
therefor
use
potent
fulli
human
hbsab
least
potenc
hbig
neutral
hbv
infect
vitro
show
togeth
tdf
antivir
treatment
synerget
effect
show
potenti
use
patient
alreadi
antivir
treatment
three
dose
infus
result
hbsag
clearanc
hdihbv
model
find
suggest
extens
hbsab
treatment
decreas
hbsag
extrem
low
level
could
restor
host
immun
respons
clear
antigen
base
find
activ
immun
hbsaghbsab
immun
complex
use
stimul
effect
host
respons
hbsaghbsab
immun
complex
therapeut
vaccin
establish
laboratori
phase
iib
clinic
trial
six
inject
per
month
follow
six
month
shown
result
hbeag
seroconvers
rate
around
addit
vaccin
shown
decreas
percentag
regulatori
cell
increas
helper
cell
cytotox
cell
ad
mous
version
therapeut
vaccin
sandwich
strategi
effici
induc
hbsagspecif
humor
cellular
immun
respons
exist
hbsabsecret
plasma
cell
found
bone
marrow
consist
high
level
hbsab
product
support
conclus
sandwich
strategi
inde
trigger
effect
humor
immun
respons
importantli
histolog
studi
show
sandwich
therapi
evok
effici
immun
respons
liver
immun
cell
infiltr
carrier
mice
liver
presenc
mhc
ii
myeloid
cell
cell
form
aggreg
lobul
area
togeth
upregul
granzym
b
product
infiltr
cell
highli
accord
significantli
downregul
express
hbsag
hbcag
liver
evid
effect
immun
respons
elicit
target
liver
concern
sandwich
treatment
infus
hbsab
bind
hbsag
form
immun
complex
vivo
might
lead
immun
patholog
nephriti
cardiovascular
inflamm
studi
singl
treatment
result
either
acut
five
day
longterm
three
month
hepat
damag
renal
heart
inflamm
postinfus
supplementari
fig
addit
advers
complic
report
chb
patient
receiv
highdos
hbig
treatment
although
immun
cell
infiltr
mous
liver
studi
find
obviou
alt
elev
singl
sandwich
treat
mice
previou
studi
present
data
indic
safeti
antibodybas
therapeut
treatment
strategi
chb
patient
howev
protocol
optim
improv
efficaci
care
evalu
safeti
sandwich
strategi
futur
clinic
trial
merit
studi
concept
design
ymw
tli
zhi
acquisit
data
bss
cyw
xfl
fy
analysi
interpret
data
bss
cyw
fy
tli
ylw
draft
manuscript
bss
tli
ylw
ymw
critic
review
manuscript
ymw
tli
zhi
bw
statist
analys
bss
cyw
materi
support
ymw
tli
jhl
zli
zhi
mfl
studi
supervis
ymw
tli
zhi
author
read
approv
final
version
paper
correspond
author
ymw
tli
zhi
confirm
full
access
data
studi
final
respons
decis
submit
public
work
support
nation
natur
scienc
foundat
china
bisheng
shi
formal
analysi
resourc
write
origin
draft
write
review
edit
yanl
wu
formal
analysi
write
review
edit
chunyu
wang
resourc
formal
analysi
write
origin
draft
xiaofang
li
formal
analysi
fan
yu
formal
analysi
write
origin
draft
bin
wang
project
administr
zhenlin
yang
supervis
jianhua
li
supervis
mifang
liang
supervis
yumei
wen
data
curat
formal
analysi
project
administr
resourc
supervis
write
origin
draft
write
review
edit
tianlei
ying
data
curat
formal
analysi
project
administr
resourc
supervis
write
origin
draft
write
review
edit
zhenghong
yuan
data
curat
formal
analysi
project
administr
supervis
write
review
edit
author
declar
conflict
interest
